Team:NTU-Singapore/Project

From 2008.igem.org

(Difference between revisions)
m
m
Line 6: Line 6:
<div id="body" style="margin-top:200px;width:950px;padding:5px;">
<div id="body" style="margin-top:200px;width:950px;padding:5px;">
-
<div id="maincontent" style="width:700px;float:left;margin-top:-30px;margin-left:10px;padding:5px;border-style:inset;">
+
<div id="maincontent" style="width:900px;float:left;margin-top:-30px;margin-left:10px;padding:5px;border-style:inset;">
=Introduction=
=Introduction=
The focus of the NTU iGEM team’s project is the use of bacteriocins as antimicrobials. This objective will be achieved by re-engineering the genome of a non-pathogenic Escherichia coli, (E.coli) strain, making it capable of colicin E7 production. The E. Coli would then function as a carrier for colicin E7 which would then induce cell death in a pathogenic strain of E. coli, O157:H7.<br>
The focus of the NTU iGEM team’s project is the use of bacteriocins as antimicrobials. This objective will be achieved by re-engineering the genome of a non-pathogenic Escherichia coli, (E.coli) strain, making it capable of colicin E7 production. The E. Coli would then function as a carrier for colicin E7 which would then induce cell death in a pathogenic strain of E. coli, O157:H7.<br>

Revision as of 05:29, 19 June 2008


Introduction

The focus of the NTU iGEM team’s project is the use of bacteriocins as antimicrobials. This objective will be achieved by re-engineering the genome of a non-pathogenic Escherichia coli, (E.coli) strain, making it capable of colicin E7 production. The E. Coli would then function as a carrier for colicin E7 which would then induce cell death in a pathogenic strain of E. coli, O157:H7.
E. coli O157:H7 is an enterohemorrhagic strain, i.e. it causes hemorrhagic colitis (bloody diarrhea). In some cases, infection by O157:H7 leads to acute renal failure. Current treatments of the infection, known commonly as EHEC, include blood transfusion and dialysis, as O157:H7 is resistant to existing antibiotics available in the market.
Besides functioning as a carrier of colicin E7, our proposed system is able to detect symptoms of EHEC, specifically, internal hemorrhaging and presence of the bacteria. Upon detection of the two forementioned, the system would trigger the synthesis of a lysis gene, which would release the colicin E7, allowing it to attack the pathogenic strain O157:H7.